ERLOCIP is a targeted anticancer drug that blocks epidermal growth factor receptors (EGFR), slowing the growth and spread of tumour cells.
Recommended for:
Patients with non-small cell lung cancer
Treatment of locally advanced or metastatic pancreatic cancer
Tumour progression after chemotherapy
Maintenance therapy for EGFR-positive tumours
Non-small cell lung cancer, metastatic pancreatic cancer, EGFR-positive malignancies.
Take orally, preferably on an empty stomach, once daily. The dosage is determined by the physician based on the patient’s condition and treatment protocol. Avoid grapefruit juice during treatment.
Contraindications:
Hypersensitivity to erlotinib or excipients
Severe liver or kidney disease
Pregnancy and breastfeeding
Age under 18 years
Side Effects:
Diarrhoea, nausea, vomiting
Skin rash and dryness
Loss of appetite
Fatigue
Abdominal pain
Liver function abnormalities (elevated enzymes)
